Edwards Lifesciences Corp (EWL.SG)
| Previous Close | 80.97 |
| Open | 80.36 |
| Bid | 80.42 x 50000 |
| Ask | 80.68 x 50000 |
| Day's Range | 80.20 - 80.48 |
| 52 Week Range | 57.26 - 88.38 |
| Volume | |
| Avg. Volume | 46 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
IRVINE, Calif., April 18, 2024--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
- Business Wire
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
ATLANTA, April 07, 2024--Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families. The findings of this study, which identified a significant discrepancy between participant self-awareness and actual prevalence of heart disease and associated risk factors, were presented today during a late-breaking clinical
- Business Wire
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
WASHINGTON, March 11, 2024--Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.
